Figure 6
CASPASE3 and MMP-9 relative gene expression in HepG2 cancer treated cells. Effect of treatment with sorafenib in presence and absence of bevacizumab, panitumumab and ramucirumab on the expression of CASPASE3 (A) and MMP-9 (B) in HepG2 cancer cells determined by RT-PCR. Each value represents the mean ± SD (n = 3). *P < 0.05 compared to HepG2 untreated cancer cells (control). #P < 0.05, compared to sorafenib treated HepG2 cancer cells.
